Eisai: Approval of Antiepileptic Drug Fycompa in Japan for Monotherapy and Pediatric Indications for Partial-Onset Seizures, as well as a New Formulation

Jan 23, 2020 15:46 JST

Source: Eisai

TOKYO, Jan 23, 2020 - (JCN Newswire) - Eisai Co., Ltd. has obtained the approvals of supplementary new drug applications in Japan for its in-house developed antiepileptic drug (AED) Fycompa (perampanel) for an additional indication for monotherapy of partial-onset seizures and an additional indication for partial-onset seizures in pediatric patients aged 4 years and older, as well as a new fine granule formulation.

The approval for monotherapy for partial-onset seizures is based on the results of a Phase III clinical study (FREEDOM/Study 342) conducted in Japan and South Korea. The outcome achieved the primary endpoint, with the rate of complete seizures-free exceeding the initially established efficacy criteria* in monotherapy for untreated epilepsy patients aged 12 to 74 years with partial-onset seizures. The most common adverse events (incidence of 10% or higher) observed in this study were dizziness, somnolence, nasopharyngitis, and headache, which were consistent with the safety profile of Fycompa to date.

The additional approval covering partial-onset seizures in pediatric epileptic patients 4 years of age and older is based on the results of a Phase III clinical study (Study 311) of Fycompa, as adjunctive therapy in pediatric patients, conducted in Japan, the United States and Europe. This study showed that the safety and efficacy of Fycompa combination therapy in pediatric epilepsy patients with poorly controlled partial seizures (ages 4 to less than 12 years) were similar to those in patients aged 12 years and older.

The additional approval for the fine granule formulation is based on the results of a bioequivalence study of fine granules and tablets conducted in Japan. Eisai developed this formulation to make it easier to administer Fycompa to children and patients who have difficulty taking tablets. The study confirmed the bioequivalence of fine granules and tablets.

Fycompa is a first-in-class AED and a once-daily oral drug discovered at Eisai's Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Fycompa has been approved in many countries around the worldwide as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older and as an adjunctive treatment for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. In the United States, Fycompa is also indicated for monotherapy and adjunctive use in the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older.

The number of epilepsy patients in Japan is estimated to be approximately 1 million, and it is possible that the disease may occur regardless of age group, but it is said that the incidence is particularly high in children and the elderly. Eisai considers neurology including epilepsy as a priority disease area, and provides information on the appropriate use of Fycompa, aiming to satisfy the diverse needs of patients and their families and offer improved benefits. With the approval for monotherapy, pediatric indication aged 4 years and older and fine granule formulation, Eisai will continue to prioritize the provision of safety information. Furthermore, Eisai will pursue its mission of delivering "seizure freedom" to as many patients as possible.

*The criteria for efficacy in this study with 73 patients for evaluation of efficacy required a 52.1% or higher proportion of patients to have achieved seizure freedom, which was set primarily in consideration of the results from other AED monotherapy studies.

Contact:

Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Related Press Release

"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month

September 12 2025 12:20 JST

Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025

September 08 2025 16:49 JST

Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025

September 04 2025 09:56 JST

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

September 03 2025 10:32 JST

FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

September 01 2025 12:44 JST

Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma

August 29 2025 17:17 JST

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)

August 25 2025 18:30 JST

Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China

August 18 2025 08:11 JST

Revenue of LEQEMBI(R) (Preliminary Basis)

July 31 2025 17:27 JST

Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC

July 31 2025 08:30 JST

More Press release >>

Latest Press Release

Honda Develops New "Chemical Sorting" Technology to Separate Solid Contaminants from Waste Plastics Derived from End-of-life Automobiles
Sep 16, 2025 15:00 JST

NEC Publishes ESG Initiatives Supporting Sustainable Growth of Companies and Society in "ESG Databook 2025"
Sep 16, 2025 14:00 JST

JSR Corporation/Inpria Corporation and Lam Research Enter Cross Licensing and Collaboration Agreement to Advance Semiconductor Manufacturing
Sep 16, 2025 09:00 JST

Toyota Launches Next-Generation New Mobility e-Palette
Sep 15, 2025 15:33 JST

The University of Osaka D3 Center Commences Operation of New Computing and Data Infrastructure Built by NEC
Sep 12, 2025 15:08 JST

GR Yaris "Aero performance package" Set for Japan Launch
Sep 12, 2025 14:40 JST

Mitsubishi Heavy Industries Achieves Target Performance at Pilot Plant for Bioethanol Membrane Dehydration Systems

Sep 12, 2025 14:19 JST

"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sep 12, 2025 13:20 JST

TANAKA PRECIOUS METAL TECHNOLOGIES Succeeds in Developing High-Performance Palladium Alloy Hydrogen Permeable Membrane Operable in the Low-Temperature Range of 300 degrees C
Sep 12, 2025 11:00 JST

CO2NNEX(R) Digital Platform for Transfer and Management of e-Methane Clean Gas Certificates to Be Utilized in Nagaoka Methanation Demonstration
Sep 11, 2025 20:37 JST

Hitachi accelerates growth with major U.S. investments in advanced manufacturing, electrification and workforce development

Sep 11, 2025 18:35 JST

GlobalLogic and Ericsson Deploy Private 5G Network at Hitachi Rail's State-of the-Art Digital Factory
Sep 11, 2025 17:24 JST

GlobalLogic and Flexware Innovation Announce Major Deployment of LIFT at Hitachi Rail's State-of-the-Art Train Manufacturing Facility
Sep 11, 2025 16:46 JST

JCB Unveils New Brand Message in Vietnam: "Japan Cung Ban"
Sep 11, 2025 13:00 JST

Kawasaki City becomes first dekokatsu subsidy municipality for promoting decarbonization lifestyle promotion project
Sep 11, 2025 10:35 JST

TGR Plans to Reproduce Engine Parts for Corolla Levin / Sprinter Trueno (AE86)
Sep 10, 2025 18:11 JST

TANAKA Acts as Category Sponsor for the LIGA.i Blind Soccer Top League 2025
Sep 10, 2025 03:00 JST

Toyota Submits Fourth Progress Report on Measures to Prevent Recurrence
Sep 09, 2025 19:26 JST

The 46th Honda Prize 2025 Awarded to Dr. Kenichi IGA
Sep 09, 2025 19:06 JST

Lexus world premieres the new IS
Sep 09, 2025 18:26 JST

More Latest Release >>